申请人:Pharmacyclics, Inc.
公开号:US20150158865A1
公开(公告)日:2015-06-11
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
本文披露了布鲁顿酪氨酸激酶(Btk)的可逆和不可逆抑制剂。还披露了包括这些化合物的药物组合物。描述了使用Btk抑制剂的方法,单独或与其他治疗剂联合用于治疗自身免疫疾病或症状、异种免疫疾病或症状、包括淋巴瘤在内的癌症,以及炎症性疾病或症状。